Lead Product(s) : Ifebemtinib,Garsorasib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
InxMed Reports Positive Results for Ifebemtinib and Garsorasib in NSCLC
Details : InxMed investigational product IN10018 (Ifebemtinib), a FAK inhibitor, is being evaluated in combination with garsorasib, for the first-line treatment of non-small cell lung cancer.
Brand Name : IN10018
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 30, 2024
Lead Product(s) : Ifebemtinib,Garsorasib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ifebemtinib,Pegylated Liposomal Doxorubicin
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The data showed that patients receiving combination of IN10018 (BI 853520) with PLD demonstrated promising antitumor activities and manageable safety profile in PROC patients, with a high overall response rate (ORR) of 56.7%.
Brand Name : BI 853520
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 27, 2022
Lead Product(s) : Ifebemtinib,Pegylated Liposomal Doxorubicin
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Hyfinity Investments
Deal Size : $15.0 million
Deal Type : Series B Financing
Details : InxMed will use the funds to accelerate ongoing clinical trials of IN10018 (BI 853520) for multiple cancer types in both US and China, including the initiation of pivotal trials, and advance more stroma targeting pipelines into clinics in both US and Chi...
Brand Name : BI 853520
Molecule Type : Small molecule
Upfront Cash : Undisclosed
May 09, 2022
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Hyfinity Investments
Deal Size : $15.0 million
Deal Type : Series B Financing
Lead Product(s) : Ifebemtinib,Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
US FDA Grants Fast Track Designation to InxMed's IN10018
Details : Early clinical data of IN10018 has demonstrated a favorable safety profile and promising efficacy signals against a number of tumor types.
Brand Name : BI 853520
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 19, 2021
Lead Product(s) : Ifebemtinib,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Ennovation Ventures
Deal Size : $19.0 million
Deal Type : Series A Financing
InxMed Announced the Completion of RMB 130M (~US$ 19M) Series A+ Financing
Details : Funding will support the acceleration of IN10018 clinical program and expand InxMed's portfolio. IN10018 is a potent and selective ATP-competitive focal adhesion kinase small molecule inhibitor.
Brand Name : BI 853520
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 03, 2020
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Ennovation Ventures
Deal Size : $19.0 million
Deal Type : Series A Financing
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The combination of KRAS G12C inhibitors and IN10018 induced FAK signaling by KRAS G12C inhibition, serving as one predominant mechanism of drug resistance of KRAS G12C inhibition, and IN10018 significantly decreases the FAK signaling induced by KRAS G12C...
Brand Name : IN10018
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 23, 2020
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
InxMed Announces Dosing of First Patient in a Phase Ib Trial of IN10018
Details : The trial will include 6 study sites in the U. S and 3 study sites in Australia, and evaluate the safety, tolerability, PK and antitumor activities of IN10018 as monotherapy with Roche's Cobimetinib.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 16, 2020
Lead Product(s) : Ifebemtinib,Cobimetinib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ifebemtinib,Pembrolizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : InxMed will be the study sponsor and MSD will provide pembrolizumab to InxMed to use in the clinical study. This is the first global clinical collaboration between the two companies.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 06, 2020
Lead Product(s) : Ifebemtinib,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?